Melinta Therapeutics, Inc. (NasdaqGS:MLNT) intends to use the net proceeds from the sale of any securities offered under the prospectus for general corporate purposes, including funding of the development programs, commercial planning and sales and marketing expenses, general and administrative expenses, acquisition or licensing of additional products, product candidates or businesses and working capital. Pending these uses, the company may invest the net proceeds in short-term, interest bearing investment grade securities, certificates of deposit or direct or guaranteed obligations of the U.S. government. The company has not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain Broad’s discretion over the allocation of net proceeds.